The Future's Bright For Microbiome Investing, Says VC
Executive Summary
Seventure Partners’ Eric de la Fortelle explains how the venture capitalist’s €160bn fund will prosper from the increased understanding of human and microbe interactions.
You may also be interested in...
Seventure Expects Uptick In Microbiome-Focused VC Investments
Having closed a €160m venture fund focusing exclusively on microbiome-related fields – including pharmaceuticals, nutrition, biomarkers and diagnostics – Seventure Partners president and CEO Isabelle de Cremoux reveals how she expects to add another 10 companies this year to the nine she already has in her portfolio.
Microbiome Market Value To Reach $500m by 2022
The microbiome market will see its value rise to $500m by 2022, and higher during the next decade. The key driver will be the increase in biotech and pharma firms looking at the emerging research space for new therapeutic options to treat chronic conditions such as Crohn’s disease.
AI Firm Healx Raises $56M To Develop Affordable Rare Disease Treatments
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.